ISDA

Deposition Date 2021-12-20

Release Date 2022-09-07

Last Version Date 2024-10-30

Entry Detail

PDB ID:

7WCE

Keywords:

HYDROLASE

Title:

Crystal structure of HIV-1 integrase catalytic core domain in complex with (2S)-2-(tert-Butoxy)-2-(10-fluoro-2-(2-hydroxy-4-methylphenyl)-1,4-dimethyl-5-(methylsulfonyl)-5,6-dihydrophenanthridin-3-yl)acetic acid

Biological Source:

Source Organism:

Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) (Taxon ID: 11698)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.85 Å

R-Value Free:

0.21

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

P 31 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Integrase catalytic
Gene (Uniprot):gag-pol
Mutations:F1332K
Chain IDs:A
Chain Length:166
Number of Molecules:1
Biological Source:Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE)

UniProt ID:P12497 Pfam ID:PF00665

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
CAF	A	CYS	modified residue

Ligand Molecules

8Z3

GOL

SO4

Primary Citation

Discovery of tricyclic HIV-1 integrase-LEDGF/p75 allosteric inhibitors by intramolecular direct arylation reaction.

Taoda, Y, Akiyama, T, Tomita, K, Fujiwara-Kitamura, M, Tamura, Y, Kawasuji, T, Matsuoka, E, Akihisa, E, Seki, T, Yoshinaga, T.Show

Bioorg.Med.Chem.Lett. 64 128664 128664 (2022)

PMID: 35272008 DOI: 10.1016/j.bmcl.2022.128664

Abstact

We have been conducting exploratory research to develop human immunodeficiency virus type-1 (HIV-1) integrase-LEDGF/p75 allosteric inhibitors (INLAIs). Here, we report on a newly designed compound with a tricyclic scaffold that shows promise as an inhibitor. Various scaffolds were synthesized by intramolecular direct arylation reaction to fix the position of a lipophilic side chain required for antiviral activity. Among these, the compound having an N-mesyl dihydrophenanthridine ring showed the best antiviral activity. Compound 42i, prepared by side chain optimization of the C-4 and C-6 positions, exhibited high antiviral activity against wild-type (WT) and the T174I mutant (EC50 (WT) = 4.6 nM, EC50 (T174I) = 83 nM) with a good PK profile. Based on co-crystal structural analysis of compound 42i and WT HIV-1 IN CCD, we discuss the interaction important for high antiviral activity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures